Ipsen to acquire U.S.-based Epizyme for $247 million.
June 27, 2022 at 02:12 AM EDT
The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
| ||||||